Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,362,356
  • Shares Outstanding, K 661,230
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • 60-Month Beta 0.99
  • Price/Sales 7.90
  • Price/Cash Flow 23.03
  • Price/Book 3.99
Trade GMAB with:

Options Overview Details

View History
  • Implied Volatility 35.01% ( +0.43%)
  • Historical Volatility 36.62%
  • IV Percentile 48%
  • IV Rank 34.45%
  • IV High 74.46% on 05/29/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 588
  • Open Int (30-Day) 701

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.28
  • Number of Estimates 7
  • High Estimate 0.33
  • Low Estimate 0.26
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.56 +1.31%
on 06/10/24
30.41 -8.19%
on 05/15/24
-0.92 (-3.19%)
since 05/10/24
3-Month
27.42 +1.84%
on 05/02/24
31.88 -12.42%
on 03/13/24
-2.38 (-7.85%)
since 03/08/24
52-Week
26.32 +6.08%
on 02/13/24
42.72 -34.64%
on 07/28/23
-10.59 (-27.50%)
since 06/09/23

Most Recent Stories

More News
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 28.07 (-1.78%)
ABBV : 170.46 (+0.61%)
JNJ : 147.13 (+0.03%)
RHHBY : 33.4600 (-0.27%)
GMAB : 27.92 (+0.54%)
AZN : 80.21 (+0.24%)
DSNKY : 36.8600 (-0.59%)
MRK : 131.49 (+0.63%)
LLY : 865.00 (+1.77%)
NVO : 143.63 (+0.52%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 27.92 (+0.54%)
IOVA : 8.06 (+3.60%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 20.00 (unch)
SGEN : 228.74 (-0.07%)
GMAB : 27.92 (+0.54%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 107.49 (-0.08%)
RHHBY : 33.4600 (-0.27%)
AMGN : 304.72 (-0.10%)
GMAB : 27.92 (+0.54%)
ABBV : 170.46 (+0.61%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 18.29 (-0.54%)
AMGN : 304.72 (-0.10%)
GMAB : 27.92 (+0.54%)
JNJ : 147.13 (+0.03%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 170.46 (+0.61%)
GMAB : 27.92 (+0.54%)
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCOREâ„¢...

ABBV : 170.46 (+0.61%)
GMAB : 27.92 (+0.54%)
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

RARE : 41.97 (+1.38%)
GMAB : 27.92 (+0.54%)
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...

GMAB : 27.92 (+0.54%)
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk

Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.

HOLX : 73.97 (-0.72%)
SPLK : 156.90 (+0.25%)
NOW : 709.15 (+1.48%)
GMAB : 27.92 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 28.40
2nd Resistance Point 28.16
1st Resistance Point 28.04
Last Price 27.92
1st Support Level 27.68
2nd Support Level 27.44
3rd Support Level 27.32

See More

52-Week High 42.72
Fibonacci 61.8% 36.46
Fibonacci 50% 34.52
Fibonacci 38.2% 32.58
Last Price 27.92
52-Week Low 26.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar